Cutaneous Leishmaniasis in Travellers: a Focus on Epidemiology and Treatment in 2015

摘要: Imported cutaneous leishmaniasis (CL) is a growing problem with increasing global travel to endemic areas. Returned travellers seeking care encounter significant barriers treatment, including diagnostic delays and difficult access anti-leishmanial drugs. Treatment recommendations in non-endemic settings are moving target, reflecting recent developments Leishmania diagnostics therapeutics. Accumulating experience molecular-based species identification has enabled species-directed therapy. Clinicians reevaluating more toxic traditional regimens light of newly approved therapeutic agents emerging data on local treatments. Referral centers implementing treatment decision algorithms designed maximize efficacy while minimizing adverse events. Although management strategies continue evolve, CL remains controversial. Persistent reliance expert opinion reflects lack research focused limited randomized controlled trial evidence. We herein review the current epidemiology species-specific evidence for available therapies.